Medication
PMS-Montelukast
DIN 02354985 · Pharmascience Inc Likely a generic
What it is
- Active ingredients
- Montelukast — 5 mg
- Form and route
- Tablet (Chewable) · Oral
- Schedule
- PRESCRIPTION
- Authorised since
- 2011-10-11
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
- Singulair
- Sandoz Montelukast
- Teva-Montelukast
- Apo-Montelukast
- Montelukast
- Montelukast
- Montelukast
- Mint-Montelukast
- Auro-Montelukast Chewable Tablet
- Jamp Montelukast Chewable Tablets
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Ontario Drug Benefit coverage
As of 31 July 2026Off-formulary interchangeable Part III-B
Ontario has designated this product interchangeable with a brand product, but it is not an ODB benefit — Part III-B, Off-Formulary Interchangeable. Ontario does not pay for it under the benefit list.
It may be funded through the Exceptional Access Program, which needs a patient-specific application from a prescriber and is decided case by case.
- What ODB pays per unit
- $1.2075
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 5mg Chew Tab and will substitute one for another at a pharmacy counter in Ontario.
- Apo-Montelukast 02377616Apotex Inc
- Auro-Montelukast Chewable Tablet 02422875Auro Pharma Inc
- Jamp Montelukast Chewable Tablets 02514885Jamp Pharma Corporation
- Mint-Montelukast 02408635Mint Pharmaceuticals Inc
- Montelukast 02379325Sanis Health Inc
- Montelukast 02382466Sivem Pharmaceuticals ULC
- Sandoz Montelukast 02330393Sandoz Canada Incorporated
- Singulair 02238216Organon Canada Inc.
- Teva-Montelukast 02355515Teva Canada Limited
Ontario lists 4 further products in this group that are not currently marketed in Canada. They are not shown.
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Respiratory system
- ATC code
- R03DC03
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of R03DC03, see the WHO ATC/DDD Index.
Recalls and safety alerts
Recall matching is not available yet.
RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.